Abscess

Acelyrin, Inc. Investor Update: Kaplan Fox & Kilsheimer LLP Notifies Acelyrin Investors of a Class Action Lawsuit and Upcoming Deadline

Retrieved on: 
Wednesday, December 13, 2023

If you purchased Acelyrin securities and would like to discuss this notice, your rights, or your interests please click here .

Key Points: 
  • If you purchased Acelyrin securities and would like to discuss this notice, your rights, or your interests please click here .
  • WHY CONTACT KAPLAN FOX - Kaplan Fox is a leading national law firm focusing on complex litigation with offices in New York, Oakland, Los Angeles, Chicago and New Jersey.
  • With over 50 years of experience in complex litigation, Kaplan Fox offers the professional experience and track record that clients demand.
  • For more information about Kaplan Fox & Kilsheimer LLP, you may visit our website at www.kaplanfox.com .

ACELYRIN, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses; January 16, 2024 deadline

Retrieved on: 
Wednesday, December 13, 2023

​LOS ANGELES, Dec. 12, 2023 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises ACELYRIN, Inc. (“Acelyrin” or the “Company”) (NASDAQ: SLRN) investors that a lawsuit filed on behalf of investors that purchased Acelyrin securities between May 4, 2023 and September 11, 2023, inclusive (the “Class Period”).

Key Points: 
  • Investors are encouraged to contact attorney Lesley F. Portnoy , by phone 844-767-8529 or email : [email protected], to discuss their legal rights, or click here to join the case via www.portnoylaw.com .
  • The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors’ options for pursuing claims to recover their losses.
  • The announcement revealed that izokibep did not achieve statistical significance in reducing abscesses and inflammatory nodules in patients compared to a placebo.
  • The Portnoy Law Firm represents investors in pursuing claims caused by corporate wrongdoing.

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against ACELYRIN, Inc. (SLRN)

Retrieved on: 
Tuesday, December 12, 2023

You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.

Key Points: 
  • You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.
  • In May 2023, Acelyrin conducted its initial public offering (“IPO”), selling 30 million shares of common stock at $18 per share.
  • To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.
  • Glancy Prongay & Murray LLP, Los Angeles

SLRN INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that ACELYRIN, Inc. Investors with Substantial Losses Have Opportunity to Lead Case

Retrieved on: 
Monday, December 11, 2023

If you suffered substantial losses and wish to serve as lead plaintiff of the ACELYRIN class action lawsuit, please provide your information here:

Key Points: 
  • If you suffered substantial losses and wish to serve as lead plaintiff of the ACELYRIN class action lawsuit, please provide your information here:
    You can also contact attorney J.C. Sanchez of Robbins Geller by calling 800/449-4900 or via e-mail at [email protected] .
  • A lead plaintiff acts on behalf of all other class members in directing the ACELYRIN class action lawsuit.
  • The lead plaintiff can select a law firm of its choice to litigate the ACELYRIN class action lawsuit.
  • An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff of the ACELYRIN class action lawsuit.

SLRN Class Action Reminder: Kessler Topaz Meltzer & Check, LLP Reminds Acelyrin, Inc. (SLRN) Investors of Securities Fraud Class Action Lawsuit

Retrieved on: 
Friday, December 8, 2023

The action charges Acelyrin with violations of the federal securities laws, including omissions and fraudulent misrepresentations relating to the company’s business, operations, and prospects.

Key Points: 
  • The action charges Acelyrin with violations of the federal securities laws, including omissions and fraudulent misrepresentations relating to the company’s business, operations, and prospects.
  • As a result of Acelyrin’s materially misleading statements and omissions to the public, Acelyrin’s investors have suffered significant losses.
  • Kessler Topaz Meltzer & Check, LLP encourages Acelyrin investors who have suffered significant losses to contact the firm directly to acquire more information.
  • The lead plaintiff selects counsel to represent the lead plaintiff and the class and these attorneys, if approved by the court, are lead or class counsel.

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against ACELYRIN, Inc. (SLRN)

Retrieved on: 
Thursday, December 7, 2023

You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.

Key Points: 
  • You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.
  • In May 2023, Acelyrin conducted its initial public offering (“IPO”), selling 30 million shares of common stock at $18 per share.
  • To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.
  • Glancy Prongay & Murray LLP, Los Angeles

ACELYRIN INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Acelyrin To Contact Him Directly To Discuss Their Options

Retrieved on: 
Thursday, December 7, 2023

NEW YORK, Dec. 07, 2023 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Acelyrin, Inc. (“Acelyrin” or the “Company”) (NASDAQ: SLRN) and reminds investors of the January 16, 2024 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Key Points: 
  • If you suffered losses exceeding $50,000 investing in Acelyrin securities between May 4, 2023 and September 11, 2023 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext.
  • Faruqi & Faruqi is a leading minority and Woman-owned national securities law firm with offices in New York, Pennsylvania, California and Georgia.
  • Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.
  • Faruqi & Faruqi, LLP also encourages anyone with information regarding Acelyrin’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

SLRN INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that ACELYRIN, Inc. Investors with Substantial Losses Have Opportunity to Lead Case

Retrieved on: 
Tuesday, December 5, 2023

If you suffered substantial losses and wish to serve as lead plaintiff of the ACELYRIN class action lawsuit, please provide your information here:

Key Points: 
  • If you suffered substantial losses and wish to serve as lead plaintiff of the ACELYRIN class action lawsuit, please provide your information here:
    You can also contact attorney J.C. Sanchez of Robbins Geller by calling 800/449-4900 or via e-mail at [email protected] .
  • A lead plaintiff acts on behalf of all other class members in directing the ACELYRIN class action lawsuit.
  • The lead plaintiff can select a law firm of its choice to litigate the ACELYRIN class action lawsuit.
  • An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff of the ACELYRIN class action lawsuit.

Acelyrin, Inc. Lawsuit Reminder: Contact Robbins LLP for Information About Your Rights Against Acelyrin, Inc.

Retrieved on: 
Monday, December 4, 2023

Acelyrin is a clinical biopharma company that focuses on developing and commercializing transformative medicines.

Key Points: 
  • Acelyrin is a clinical biopharma company that focuses on developing and commercializing transformative medicines.
  • For more information, submit a form , email Aaron Dumas, Jr., or give us a call at (800) 350-6003.
  • Specifically, izokibep failed to show statistically significant reduction in abscesses and inflammatory nodules in patients as compared to placebo.
  • What Now: Similarly situated shareholders may be eligible to participate in the class action against Acelyrin, Inc. Shareholders who want to act as lead plaintiff for the class should contact Robbins LLP.

Investors Say Acelyrin (SLRN) Lied About Drug Candidate’s Progress - Hagens Berman

Retrieved on: 
Monday, December 4, 2023

SAN FRANCISCO, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Hagens Berman urges Acelyrin, Inc. (NASDAQ: SLRN) investors who suffered substantial losses to submit your losses now .

Key Points: 
  • SAN FRANCISCO, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Hagens Berman urges Acelyrin, Inc. (NASDAQ: SLRN) investors who suffered substantial losses to submit your losses now .
  • Investors learned the truth on Sept. 11, 2023, when Acelyrin announced disappointing top-line results from Part B of the Phase 2b/3 trial evaluating izokibep for the treatment of moderate to severe HS.
  • This news drove the price of Acelyrin shares plummeting $17.19 lower during the two trading days ended Sept. 13, 2023.
  • “We’re focused on investors’ losses and are investigating whether Acelyrin may have concealed data that did not support the hypothesized benefits of izokibep,” said Reed Kathrein, the Hagens Berman partner leading the investigation.